Daoyuan Capital Portfolio Company Baiyouda Receives Approval for China's First Domestic Dialysis Graft
BIODALS
Implantable Medical Device Developer and Manufacturer
On December 16, 2024, CIRCULINE®, a dialysis artificial blood vessel product independently developed by Shanghai Changdy Medical Co., Ltd., a wholly-owned subsidiary of JIANGSU BIODA LIFE SCIENCE Co., LTD. ("BIODALS"), an outstanding company invested in by Daoyuan Capital, successfully obtained the Innovative Medical Device Registration Certificate (Registration No. 20243132518) issued by the National Medical Products Administration, marking the official entry of this innovative product into the market.
Since its establishment, BIODALS has been focusing on the research, development, and production of high-end implantable and interventional medical devices. It has successively established wholly-owned subsidiaries, Shanghai Changdy Medical Co., Ltd. and Behelia. Its product portfolio includes the VASOLINE® artificial blood vessel, VASOPATH® disposable strip retractor, MONOKNIT™ hernia repair mesh, and VASO™ non-absorbable surgical suture. The recently approved dialysis artificial blood vessel product marks another significant breakthrough for the company following the first Chinese registration certificate for a large arterial artificial blood vessel.
CIRCULINE® (China Medical Device Registration No. 20243132518)It is a textile-type artificial blood vessel made by the organic combination of medical-grade high-elastic silicone and expanded polytetrafluoroethylene (ePTFE), featuring an innovative three-layer structure for dialysis. The inner layer is an ultra-thin ePTFE artificial blood vessel with molecular support rings, offering excellent biocompatibility and providing an effective anti-thrombosis channel for blood flow. The middle layer consists of medical-grade high-elastic silicone, which quickly regains its original shape after deformation, ensuring optimal needle-hole closure after dialysis puncture. The outer layer is a braided polyester artificial blood vessel, characterized by excellent suture ability, providing speed and necessary strength for suturing during surgery.
Dialysis Grafts Suitable for Arteriovenous Fistula Creation. As China's population aging process accelerates, the number of related patients continues to increase, and the market demand for dialysis grafts is also growing. For a long time, China's dialysis grafts market has mainly relied on imports. The approval of the CIRCULINE® graft product this time not only enriches the company's product line but also marks an important milestone for BIODALS in the medical device field. More importantly, it will effectively break the Western technology monopoly and alleviate the issue of heavy reliance on imported products in the Chinese market.
BIODALS Life Science Co., Ltd. was established in 2015 and currently has two production and R&D bases in Nantong and Shanghai. The BIODALS Science Park, located in the North Nantong High-tech City, covers an area of 40 mu with a plant area of 35,000 square meters, including over 10,000 square meters of clean workshops, serving as BIODALS' production base.
The company has established the BIODALS R&D Center in Zhangjiang Medipark, Shanghai, with an area of 7,000 square meters, including over 5,000 square meters of laboratory space, capable of meeting the R&D and pilot production needs for various high-end implantable and interventional medical devices and equipment. The company currently has more than 20 ongoing projects, covering multiple departments such as cardiovascular surgery, vascular surgery, cardiac surgery, and general surgery. Relying on technical platforms like polymer materials, biomaterials, and metal stent forming, the company is continuously launching more high-quality products tailored to clinical needs, benefiting a wide range of patients.
Dao Yuan Capital is a leading private equity investment institution focused on the healthcare sector, dedicated to helping outstanding healthcare companies grow rapidly by leveraging capital and industry resources, providing better medical products and services to society, and promoting human health.
Currently, Daoyuan Capital manages 19 RMB funds and 4 USD funds, with investments in 90 outstanding projects, including 16 IPO projects (one of which has obtained the CSRC registration approval), such as PuRui Ophthalmology (301239), Jinxin Fertility (HK.1951), Sino Medical (688108), Innovax (688253), Tinavi Medical Technologies (688277), Viva Biotech (HK.1873), Anbiping (688393), and Angenesis (688581). As of the latest date in 2024, two enterprises have filed for IPOs, and more than 10 invested companies are expected to enter the IPO process within the next three years.
